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Abstract 
 
The evolution of multiple antibiotic resistance is an increasing global problem. 
Resistance mutations are known to impair fitness and the evolution of resistance to 
multiple drugs depends both on their costs individually and how they interact - epistasis. 
Information on the level of epistasis between antibiotic resistance mutations is of key 
importance to understanding epistasis amongst deleterious alleles, a key theoretical 
question, and to improve public health measures. Here we show that in an antibiotic free 
environment the cost of multiple resistance is smaller than expected, a signature of 
pervasive positive epistasis amongst alleles that confer resistance to antibiotics. 
Competition assays reveal that the cost of resistance to a given antibiotic is dependent 
on the presence of resistance alleles for other antibiotics. Surprisingly we find that a 
significant fraction of resistant mutations can be beneficial in certain resistant genetic 
backgrounds, that some double resistances entail no measurable cost and that some 
allelic combinations are hotspots for rapid compensation. These results provide 
additional insight as to why multi-resistant bacteria are so prevalent and reveal an extra 
layer of complexity on epistatic patterns previously unrecognized, since it is hidden in 
genome-wide studies of genetic interactions using gene knockouts. 
 
 
Author Summary 
 
Understanding the nature of genetic interactions, known as epistasis, is crucial in 
biology. The strength and type of epistasis is relevant for the evolution of sex, buffering 
of genetic variation, speciation and the topography of fitness landscapes. While epistasis 
between gene deletions has been the recent focus of research, interactions between 
randomly selected alleles, which are of the greatest evolutionary interest has not. 
We have studied the strength and type of epistasis amongst alleles that confer antibiotic 
resistance and found that: in an antibiotic free environment the cost of multiple 
resistance is smaller than expected - a signature of pervasive positive epistasis amongst 
alleles that confer resistance to antibiotics; epistatic interactions are allele specific; a 
significant fraction of resistant mutations can be beneficial in certain resistant genetic 
backgrounds; some double resistances entail no measurable cost and some allelic 
combinations are hotspots for rapid compensation. Overall our findings provide added 
reasoning to why multi-resistance is so difficult to eradicate. Importantly our results of 
allelic specific epistasis reveal an extra layer of complexity on epistatic patterns 
previously unrecognized. 
 
 
 
Introduction 
 
Epistasis occurs when the phenotypic effect of a mutation in a locus depends on 
which mutations are present at other loci. When the phenotype of interest is fitness, the 
existence of such genetic interactions can constrain the course of evolution. The 
strength and form of epistasis is relevant for the evolution of sex, buffering of genetic 
variation, speciation and the topography of fitness landscapes. While epistasis between 
gene deletions [1,2] has been the focus of recent research, interactions between 
randomly selected alleles, which are of the greatest evolutionary interest has not [3]. 
Since mutations that confer antibiotic resistance are known to affect bacterial fitness, 
levels of epistasis amongst such mutations may determine how multiple resistance 
evolves. Such knowledge can be used to understand and predict what type of resistance 
mutations are likely to be segregating in microbial populations [4]. To understand and 
predict the evolution of multiple resistance it is of key importance to know how the 
fitness of sensitive and resistance bacteria is affected in different environments, 
particularly both in the presence and in the absence of drugs. Recent studies have shown 
that interactions exist amongst pairs of antibiotics, i.e. resistance to one drug affects the 
action of another drug [5,6]. In particular the combination of pairs of drugs has been 
studied and the combinations have been characterized as additive, synergistic, 
antagonistic or suppressive. Importantly it has been found that in certain drug 
combinations (suppressive) one of the antibiotics may render the treatment more 
effective against its resistant mutant than against the wild type [6]. However, we are 
lacking data on genetic interactions amongst single nucleotide mutations conferring 
antibiotic resistance in a drug free environment, i.e. the cost of multiple resistance. With 
the occurring increase in frequency of multiple resistant bacteria and the public health 
problems associated with it, knowledge on the type and strength of epistasis is of most 
importance in understanding the evolution of multiple resistance and, ultimately, the 
planning of new strategies for human intervention. 
One can think that a way to halt the spread of resistance to a given antibiotic is to 
stop the use of that antibiotic. In the absence of the antibiotic for which resistance has 
been acquired, antibiotic-resistance mutants have a fitness cost when compared to 
sensitive bacteria [7,8]. However, when infection is not resolved, a common strategy is 
to continue treatment with a different antibiotic to which the infecting bacteria are still 
susceptible. Unfortunately this strategy has led to rapid increase in multiple-drug 
resistance and not to the loss of resistance to the first treatment, as it would be desired 
[9]. This raises the possibility that multi-resistant mutations are not independent. If so, 
when resistance first develops the following question should be asked: if a pathogenic 
strain is resistant to antibiotic X, which antibiotic should be administered as a second 
treatment?  Clearly, the strategy will depend not only on knowledge about the fitness 
costs of single resistance mutations but also on the level of genetic interactions – 
epistasis - between the alleles that underlie those phenotypes.  When epistasis exists, it 
can be positive (antagonistic or alleviating) or negative (synergistic or aggravating). If 
strong negative epistasis amongst drug resistance alleles is found, then the cost of 
multiple resistances is high and one can expect multi-drug resistant microbes to be 
counter selected and disappear very rapidly in the absence of either drug. On the 
contrary, a much more worrying scenario is the existence of positive epistasis, for it 
implies that the expected time for elimination of multiple resistance, even if antibiotic 
pressure is inexistent, will be much longer and multiple resistant bacteria are expected 
to accumulate in the population.  
Here we quantify the degree of genetic interactions on cellular fitness in an 
antibiotic free environment for point mutations which confer resistance to commonly 
used antibiotics of three different classes. We have focused on resistances to: (i) the 
quinolone nalidixic acid, which inhibits DNA replication by binding to DNA gyrase; (ii) 
rifampicin, which belongs to the rifamycins class of antibiotics that bind to the β-
subunit of RNA polymerase thereby inhibiting transcription; and (iii) streptomycin, an 
aminoglycoside that binds to the ribosome and inhibits elongation of protein synthesis 
[10]. We find that epistasis is allele specific and that the vast majority of allelic 
combinations exhibit positive epistasis. The costs of double resistance are therefore 
smaller than what one would expect if they were independent. Interestingly we found 
several cases of sign epistasis, which implies that mutations conferring resistance to a 
new antibiotic are compensatory, i.e. alleviate the cost of resistance present on another 
locus.  
 
Results 
 
Single resistant mutants’ fitness costs 
To study the degree of epistatic interactions amongst alleles that confer 
antibiotic resistance we started by selecting a series of Escherichia coli spontaneous 
mutants resistant to commonly used antibiotics of 3 different classes: nalidixic acid, 
rifampicin, and streptomycin (Methods). From a panel of 120 sequenced clones that 
carry a single nucleotide change, we obtained 19 different classes of clones (Table S1) 
with spontaneous mutations in gyrA, rpoB and rpsL, which are the correspondent 
common target genes of resistance to nalidixic acid, rifampicin, and streptomycin, 
respectively. Resistant bacteria with mutations in the same amino acids as those 
collected here are segregating in microbial populations [4,11]. We should notice that our 
procedure for isolating clones carrying antibiotic resistance requires that viable colonies 
of resistant bacteria can be formed and detected. Any mutations that can arise and cause 
very high fitness costs cannot therefore be accounted for in this study. Given that highly 
deleterious mutations are unlikely to segregate in natural populations [4], genetic 
interactions amongst such mutations are likely to be of less clinical importance, unless 
these can be very easily compensated for. 
We determined the cost of resistance of each of the clones in the absence of 
antibiotics. This was performed by measuring relative competitive fitness of the 
resistant strains against a marked sensitive strain through a competition assay in liquid 
LB medium without antibiotics [12] (Methods). Figure 1A shows the distribution of 
fitness costs of each of the mutants. The genotype of each mutation as well as its fitness 
costs are provided in Table S1. On average the cost of antibiotic resistance was 9%. A 
Kolmogorov-Smirnov test does not reject the exponential distribution (P=0.85), a 
commonly used model to describe the distribution of deleterious mutations in several 
organisms [13]. Mutations that confer resistance to nalidixic acid had a lower average 
fitness cost (3%) than streptomycin or rifampicin (13% and 9%, respectively). Similar 
levels of fitness cost were found previously in resistant mutants of Mycobacterium 
tuberculosis [4,14] and E. coli [15,16]. 
 
Epistasis between deleterious mutations that confer antibiotic resistance 
 To study the fitness cost of double resistance and measure epistasis we constructed 
by P1 transduction all possible pairwise combinations (103) between different 
resistance alleles. These correspond to 5x11 streptomycin/rifampin, 5x3 streptomycin 
/nalidixic acid and 11x3 rifampin/nalidixic acid possible combinations. We measured 
the fitness of the obtained double resistant by competition assays, determined its cost 
and compared it with the cost that would be predicted if there was no epistasis. Figure 
1B shows that the average cost of double resistance is less than twice the average cost of 
a single resistance (compare with Figure 1A), indicating positive epistasis. Fitness of 
double resistance was used to calculate pairwise epistasis. Pairwise epistasis, ε, between 
locus A and B can be measured as follows [17]. If wAB is the fitness of the wildtype, 
wAb, waB are the fitnesses of each of the single mutants and wab that of the double mutant 
then:  
ε=wABwab−wAbwaB. 
When the value of the costs is small then this measure becomes very similar to the 
difference between the cost of double resistance and the sum of the costs of each 
resistance.  
Strikingly, the majority of mutations show positive epistasis. 68% of the points 
are above the line in Figure 2A and from the clones that show significant epistasis 15% 
show negative epistasis and 42% show positive epistasis. The later ones correspond to 
clones where the cost is less than the sum of the costs of each resistance (see also Figure 
2C for the specific combinations of alleles showing significant positive epistasis). 
It has been suggested from theoretical modeling of RNA secondary structures and 
from studies in digital organisms – computer programs that mutate and evolve- [18] that 
epistasis and the fitness effect of mutations may be correlated, such that mutations with 
larger effects are more epistatic. In our data we find significant correlations between the 
strength of epistasis (deviation from zero in absolute value) and the costs of the 
mutations (Pearson’s correlation r=0.61, P<0.001), which support this theoretical 
prediction. We also find a marginally significant correlation between the value of 
epistasis, ε, and the cost of the mutations (Pearson’s correlation r=0.19, P=0.06). 
Figure 2B shows the distribution of the ε values, the median is significantly positive 
(median=0.025, Bootstrap 95% CI [0.016; 0.032]), and its value corresponds to about 
1/3 of the average cost of each single mutation. From the allelic combinations for which 
there is significant epistasis (53%), only 27% give rise to negative epistasis, whereas 
73% of these combinations result in positive epistasis. Epistatic interactions were 
observed more frequently between mutations in gyrA and in rpsL, with high frequency 
of positive epistasis but also extreme cases of negative epistasis (synthetic sub-lethal, 
Figure 2C). Combination of gyrA and rpoB mutations produced the lowest frequency of 
negative epistasis (6%), which suggests that the sequential prescription of antibiotics 
leading to these resistances may easily result in multi-resistance development.  
Focusing on the mutations we notice that the interactions are not gene but allele 
specific. For example R529H and H526L mutations in rpoB notably showed very high 
negative epistasis frequency, whereas four other mutations (D516V, H526N, I572F and 
S512F) in the same gene showed no negative epistasis regardless of the combination, 
and D516V and I572F mutations revealed high frequency of positive epistasis. The 
latter are potential candidates to segregate in natural populations. The rpoB H526D 
mutation is a specific example where its epistasis is highly dependent on the particular 
allele of the second mutation: rpoB H526D interacts positively with rpsL K43N, but 
negatively with rpsL K43T. Interestingly, the rpoB H526D mutation has been found in 
multi-drug resistant M. tuberculosis strains and also in this organism its cost was shown 
to depend on the genetic background [4]. This suggests two important predictions: that 
we should find resistance alleles with strong positive interaction segregating at higher 
frequencies (such as rpoB H526D/ rpsL K43N) in natural populations and that these 
genetic interactions should also apply to microorganisms other than E. coli.   
 
Sign epistasis in antibiotic resistance mutations 
Recently it has been shown that an important type of epistasis, which is known 
as sign epistasis [19], may constrain the evolution of resistance to high penicillin 
concentrations [20]. Sign epistasis happens when the sign of the fitness effect of a 
mutation (deleterious or beneficial) is itself epistatic, i.e. sign epistasis exists when a 
mutation is deleterious on some genetic backgrounds but beneficial on others. This form 
of epistasis, if common, may give rise to multiple peaks on the fitness landscape. In the 
context of antibiotic resistance, the implication is simple: if sign epistasis is pervasive 
then it will be much more difficult to move from a scenario of multiple drug resistance 
to a scenario where all the bacteria are sensitive, even if antibiotic selection pressure is 
stopped. Experimental evolution studies have shown that, within hundreds of 
generations, mutations which compensate for the cost of antibiotic resistance 
(compensatory) are more likely to occur [16,21,22] than revertants [14]. This suggests 
that sign epistasis might have an important role for the evolution of antibiotic resistance. 
Within the allelic combinations studied, 12% of our clones showed unexpected sign 
epistasis between drug resistance alleles. This corresponds to double mutants that have a 
fitness bigger than the fitness of at least one of the single mutants (Figure 3), and here it 
means that the mutation conferring resistance to a new antibiotic is beneficial 
(compensatory) when in a genetic background that contains a mutation conferring 
resistance to a different antibiotic. This is the worst possible scenario for the host and 
the best possible for the microbe. Given that a particular mutation was just selected by 
application of an antibiotic, evolution by natural selection makes it likely that the 
fixation of a mutation conferring resistance to another antibiotic will occur, even if 
selective pressure is not applied. Specifically, we find that the same mutation conferring 
streptomycin resistance (rpsL K88E, Figure 3) can be compensated by different 
mutations that confer rifampicin resistance showing that rifampicin treatment should be 
avoided in patients infected with rpsL K88E streptomycin resistant mutants. Given these 
results, knowledge of both the clinical history of patient antibiotic use as well as the 
specific genotypes associated with a given resistance is recommended for predicting the 
optimal clinical outcomes.  
Another worrying class of clones that we found corresponds to combination of 
double resistant mutations that entail no significant cost. These are 6 out of the 103: 
rpsL K43R/gyrA D87G, rpsL K43R/gyrA D87Y, rpoB H526N/gyrA D87G, rpoB 
H526N/gyrA D87Y, rpoB D516V/gyrA D87Y, rpsL K43R/rpoB H526N. These mutants 
have no disadvantage against the wild-type. Although this constitutes a small 
percentage, it is nevertheless of extreme importance since for these double mutants 
little, if any, compensation is required for restoring the competitive ability of the wild-
type. Given the known association between the cost of resistance mutations measured in 
the laboratory and the frequency at which they are found in clinical settings has been 
demonstrated, at least in M. tuberculosis [4], we predict that those combinations of 
double mutations are the ones which are more likely to be found. Future studies are 
planned to test this prediction, although it should be noted that the target for resistance 
may vary between species and environmental conditions [23]. In the opposite extreme 
we found five clones for which the transduction efficiency was very low (combinations 
shown in black, Figure 2C) which might correspond to combinations of mutations that 
must entail high fitness cost.  
 
Level and pattern of epistasis in spontaneous double resistant clones  
To make predictions about which resistance alleles are likely to be segregating it 
is important to study the frequency at which they spontaneously arise. To query which 
of the P1 transducted mutants are likely to naturally occur and if these also show 
pervasive epistasis we collected hundreds of spontaneous double resistance mutants. 
From 289 clones that were sequenced, we obtained 76 different genotypes, whose 
frequencies are given in Figure 4. We performed a χ2-square test to investigate the 
effects of genetic background on the spectrum of mutations that spontaneously arise. 
We observe that there are significant differences between the types of new resistances 
mutations that appear in certain resistant backgrounds and the wild-type sensitive 
background (Table S2). 
We measured the fitness of each of the different spontaneous double resistant 
clones and compared it with the fitness in the corresponding clones constructed by P1 
transduction. 67 out of 72 spontaneous clones were not different from the P1 
constructed mutants (Figure S3), but surprisingly, five double resistant clones (rpoB 
S531F/gyrA D87Y; rpsL K43T/rpoB H526Y; rpsL K88R/rpoB H526D; rpsL K43R/rpoB 
S531F; rpoB I572F/rpsL K88R) had a significantly higher fitness (Wilcoxon test, 
P<0.01). These five spontaneous mutants have a higher fitness because they must have 
acquired an extra mutation during their isolation which is compensatory. To show that 
this is in fact the case we measured the fitness of independent clones carrying the same 
resistance mutations.  For three of these haplotypes (rpsL K43T/ rpoB H526Y, rpsL 
K88R/ rpoB H526D, rpsL K43R/ rpoB S531F) we measured the fitness of spontaneous 
clones which were obtained applying the reversed antibiotic selection procedure. (i.e. 
the clones were now isolated by selecting first rifampicin for and secondly for 
streptomycin). A Wilcoxon-test revealed that the fitness values of these new 
independent clones were not different from the corresponding P1 clones, showing that 
the original spontaneous clones carry a compensatory mutation. Given the reduced 
number of generations in the procedure of generating spontaneous double resistant 
mutants, observing a compensatory mutation is only probable if such mutation has a 
very strong effect (sc). This is because only with a large sc it will not be stochastically 
lost (probability of fixation ~2sc), and can fix in such short time (time to fixation ~1/sc) 
[24]. Indeed for the five mutants mentioned above, the estimated fitness effect sc is very 
large, on average 0.09 (with the corresponding effects of each compensatory mutation 
0.07; 0.13; 0.11; 0.07; 0.06). Adaptive mutations of such strong effect emerging and 
fixing so rapidly in bacterial populations under such small effective population size, is 
surprising given previous estimates of effects of beneficial mutations (on average 0.01) 
[25]. A strong compensatory mutation must also have occurred in the spontaneous 
clones carrying rpsL K43T/gyrA D87G, rpsL K43N/gyrA D87G, rpsL K43T/gyrA D87Y 
and rpsL K43N/gyrA D87Y mutations, which were determined as synthetic sub-lethals 
by P1 transduction. 
We calculated the ε values for the 67 spontaneous clones where we do not have 
evidences for extra compensatory mutations and obtained the same trend as with the 
double mutants constructed by P1 transduction (58% showed significant epistasis from 
which 74% showed positive epistasis and 7% that had no significant cost (Figure S1)). 
These results indicate that positive epistasis is also pervasive in spontaneous mutants 
supporting the relevance of our results. Additionally, there is evidence from 
epidemiological studies that in M. tuberculosis environmental resistant isolates more 
than 96% of the strains resistant to rifampicin have at least one mutation in rpoB, 52 to 
59% of the streptomycin resistant strains have mutations in rpsL and 74 to 94% of the 
strains resistant to ofloxacin or levofloxacin (quinolones like nalidixic acid used here) 
have mutations in gyrA[26]. Also, the same type of mutations have been isolated in E. 
coli [27] and in Salmonella enterica where 42% of the isolates showed substitutions in 
gyrA at position S83 and 35% at position D87 [28], that we show here to exhibit 
epistasis.  Thus we expect the traits observed to be relevant for the evolution of multi-
drug resistance acquired during treatment of infectious agents.  
    
Discussion 
 
Given the importance of epistasis in a variety of biological features such as sex 
and recombination, buffering of genetic variation, speciation, and the evolution of 
genetic architecture [29], recent studies have focused on measuring genome-wide levels 
of epistasis. However, typically only deletions or knockout mutations were studied 
[1,2,30,31].  Here, albeit focusing in a small number of genes, we measured epistasis on 
fitness at the scale of the allele given that these maybe the most common type of 
mutations segregating in natural populations and because it also allows us to study 
mutations in essential genes. Our results not only show the significance of these 
interactions for the evolution of antibiotic resistance but also reveal an extra layer of 
complexity on epistatic patterns previously unpredicted, since it is hidden in genome-
wide studies of genetic interactions using gene knockouts. 
The data obtained here revealed an average level of positive epistasis, which 
differs strongly from the results of the degree of epistasis among slightly deleterious 
mutations caused by random transposon insertions in E. coli, where on average no 
epistasis was found [30].  Positive epistasis has also been found in HIV-1 isolates [32]. 
Since the data in that study was obtained by sampling mutants from natural populations, 
comparisons between the results obtained and those found here should be taken 
carefully. We note nevertheless that some bias towards positive epistasis that may be 
present in the HIV study is not present in our study, since we constructed all possible 
pairwise combinations of double mutants. It remains to be explored whether the type of 
mutations (single nucleotide changes, deletions or tranpositions) can affect the pattern 
of genetic interaction which can be observed.  We predict that it can since we show that 
the type of interactions is not gene but allele specific. Positive epistasis was also 
detected when studying interactions between rifampin and streptomycin resistant 
mutants in Pseudomonas aeruginosa [33]. The pattern in E. coli presented here and the 
results found in P. aeruginosa (even though having a different genetic basis) [33] 
indicate that the presence of positive epistasis amongst antibiotic resistance mutations is 
not species specific. Furthermore epistatic interactions involving fluoroquinolone 
resistance mutations in gyrA have also been found in Streptococcus pneumoniae [34]. 
    Although we have studied different classes of antibiotics that affect different cell 
targets, our finding of pervasive epistasis can be reflecting the fact that these target 
genes are part of the fundamental flow from DNA to RNA to protein, and thus can be 
considered to be working in the same pathway. Because these affect highly conserved 
cell processes they should be relevant in many different organisms. An interaction 
between some of these genes has been described for specific traits, namely propagation 
of bacteriophage T7 (interaction between rpsL and rpoB) and mitomycin C resistance in 
E. coli (between rpoB and gyrA) [35,36]. 
Our data, both of spontaneous and P1 transducted double resistant clones, also 
indicates the presence of sign epistasis in the cost of multi-drug resistance involving 
rifampin, streptomycin and nalidixic acid, that is, a small fraction of double resistant 
clones showed a higher fitness than at least one of the corresponding single resistant 
mutants. Sign epistasis implies that the fixation of one mutation (for example by strong 
selection pressure of a given antibiotic) may alter the adaptive path in both number and 
type of subsequent beneficial mutations. Sign epistasis was also previously found in the 
context of resistance to the antibiotic cefotaxime [20]. In this system of the 120 possible 
mutational paths from the low resistance to high resistance only 18 can actually occur 
due to the occurrence of sign epistasis. Although there are not many examples in the 
literature [19], this one clearly shows the power of sign epistasis in constraining protein 
adaptation.  
Another interesting example in the context of this work is bacterial adaptation to 
the cost of resistance through the acquisition of new compensatory mutations. In such 
an adaptive process it was observed that adaptive mutations which reduce the cost of 
resistance to streptomycin in E. coli [37] and Salmonella [12] are deleterious in the 
streptomycin-sensitive background and therefore constitute an example of sign 
epistasis. 
In this work we have determined the fitness effect of mutations in the absence of 
antibiotics. Future studies should focus on epistatic interactions when bacteria grow in 
the presence of antibiotics, a condition already shown to be relevant to the evolution of 
resistance [38,39]. 
 
 
Our results highlight the importance of determining the costs of single and 
multiple resistances and, accordingly ordering allele combinations by the degree of 
epistasis they exhibit. Given that at the present time, infections are likely to be caused 
by microbes that carry resistance to at least one drug, the strategy expected to give the 
best outcome is one in which the next drug is the one leading simultaneously to the 
resistant mutant with the biggest cost and strongest negative epistasis. Another approach 
to prevent the evolution of multidrug resistance would be to use drug combinations (at 
certain concentrations) that select for sensitive bacteria. This is a plausible scenario 
since it has been shown that when competing in the presence of the two drugs, sensitive 
bacteria outgrow resistant [6]. Our finding of pervasive positive epistasis suggests one 
possible explanation for the difficulty of eradicating multi-drug resistance in organisms 
like M. tuberculosis, for which current treatments involve combinations of the same 
drugs as studied here.  
 
 
Methods 
 
Bacterial Strains and Growth Conditions  
      The strains used were Escherichia coli K12 MG1655 and Escherichia coli K12 
MG1655 Δara. All clones with antibiotic resistant mutations were derived from the 
ancestral strain Escherichia coli K12 MG1655. Escherichia coli K12 MG1655 Δara, 
was used as reference for the competition fitness assay. The two strains are 
distinguishable by phenotypic difference due to a deletion in the arabinose operon: ara+ 
and Δara give rise to white and red colonies, respectively, in tetrazolium arabinose (TA) 
indicator agar [12].  The clones were grown at 37o C on plates containing Luria-Bertani 
(LB) supplemented with agar and the respective antibiotics. The antibiotic 
concentrations were 100µg/ml for rifampicin, 40µg/ml for nalidixic acid and 100µg/ml 
for streptomycin. To estimate fitness costs competitions were performed during 24 
hours in 50 ml screw-cap tubes containing 10 ml of LB medium at 37oC, with aeration 
(orbital shaker at 230 RPM). To estimate the frequency of each strain, in the beginning 
and by the end of the competition, Tetrazolium Agar (TA) medium containing 1% 
peptone, 0.1% yeast extract, 0.5% sodium chloride, 1.7% agar, 1% arabinose and 
0.005% Tetrazolium chloride was used. All sets of dilutions were done in MgSO4 at a 
concentration of 0.01M. 
 
Isolation of P1 Transducted and Spontaneous Resistant Clones 
      The measure of two-locus epistasis requires the construction of double mutants from 
single mutants, in order to obtain clones with the same mutations alone and in 
combination. The antibiotics chosen to isolate the mutants were rifampicin, nalidixic 
acid and streptomycin. Sets of 40 single clones resistant to each antibiotic were obtained 
by growing independent cultures of Escherichia coli K12 MG1655, plating in Luria-
Bertani (LB) agar medium supplemented with each antibiotic and randomly selecting 
the clones after 24 hours of incubation at 37o C. Each clone was streak plated, and a 
single colony was grown in a screw-cap tube with 10 ml of LB medium supplemented 
with the respective antibiotic and stored in 15% glycerol at -80oC. Generalized 
transduction of the resistance mutations with bacteriophage P1 was performed as 
described previously [40]. These mutations were obtained by isolating spontaneous 
resistant clones and then using these as donor or recipient strains for the construction of 
the double mutants. Whereas in the great majority of clones the transduction efficiency 
was high in 5 combinations of clones it was extremely low. These clones were termed 
synthetic sub-lethals and are indicated on Figure 2C. For two combinations of double 
resistance mutations, three independent clones were assayed for fitness. No significant 
differences were observed (Kruskal-Wallis test) between these clones. 
Three single spontaneous clones, resistant to each antibiotic, were used to put 
back the resistance on the wild-type sensitive background through P1 transduction. We 
then measured in 5 fold replicate competitions the fitnesses of each spontaneous mutant 
and the corresponding single P1 transduced clone. Pairwise comparisons, by Wilcoxon 
test, revealed no significant differences between the single resistance clones constructed 
in different ways. 
We exposed the single resistant clones to a second antibiotic to select for 
spontaneous mutants resistant to two antibiotics. These were obtained by culturing each 
clone carrying resistance independently and plating in Petri-dishes with the two 
antibiotics. Clones with the double resistance were picked randomly. All spontaneous 
resistant clones were tested for a mutator phenotype and those few with evidence of 
high mutation rate were disregarded 
 
 
Detection of Mutations 
      The main target genes for resistance to rifampicin, nalidixic acid and streptomycin 
are rpoB, gyrA and rpsL, respectively. To know the mutations that confer the obtained 
resistances, each target was amplified and then sequenced. The primers used to amplify 
the portion of the rpoB gene encoding the main set of mutations conferring resistance to 
rifampicin were: 5’-CGTCGTATCCGTTCCGTTGG-3’ and 5’-
TTCACCCGGATAACATCTCGTC-3’; for gyrA gene, which encodes for the main set 
of mutations conferring resistance to nalidixic acid, 5’-
TACACCGGTCCACATTGAGG-3’ and 5’-TTAATGATTGCCGCCGTCGG-3’; for 
rpsL gene, that encodes for the mutations conferring streptomycin resistance, 5’-
ATGATGGCGGGATCGTTG-3’ and 5’-CTTCCAGTTCAGATTTACC-3’. The same 
primers were used for sequencing straight from the PCR product. 
 
Fitness Assays 
      To measure fitness cost of the resistance mutations a competition assay was done. 
The resistant mutants were competed against a reference strain, Escherichia coli K12 
MG1655 Δara in an antibiotic free environment, in an approximate proportion of 1:1. 
To do so, we grew both resistant and reference strains in LB liquid medium for 24 hours 
at 37o with aeration. Accurate values of each strain initial ratio were estimated by 
plating a dilution of the mixture in TA Agar plates. Competitions were performed in 50 
ml screw-cap tubes containing 10 ml of LB liquid medium by a period of 24 hours at 
37o with aeration. By the end of this competition process, appropriate dilutions were 
platted onto TA agar plates to obtain the final ratios of resistants and reference strains. 
The fitness cost of each mutant strain- i.e the selection coefficient - was estimated as the 
per generation difference in Malthusian parameters for the resistant strain and the 
marker strain [12], discounted by the cost of the Δara marker. The fitness cost was 
estimated as an average of four and five independent competition assays for P1 and 
spontaneous resistant clones respectively. No correlation was observed between the cost 
of the resistance mutations and the frequency at which they arose (Figure S1).  
 
Measure of Epistasis and Statistical Significance   
Pairwise epistasis, ε, can be measured assuming a multiplicative model in which 
case:  ε=WABWab−WAbWaB, whereWij is the fitness of the clone carrying alleles i and j 
and capital letters represent the wild-type sensitive alleles. Error (σε) of the value of ε is 
then estimated by the method of error propagation: 
22222222
WaBAbWAbaBWabABWABab WWWW σσσσσ ε +++= . 
Whenever the value of ε was within the error we considered that alleles a and b did not 
show any significant epistasis (we indicate such combinations as white boxes labeled no 
epistasis in Figure 2C). 
From the distribution of values of ε, provided in Figure 2B, we calculated the 
median value of ε and its 95% CI by bootstrap where we took 1000 samples. We tested 
normality of the distribution by a Shapiro-Wilk normality test P=0.024, and a Wilcoxon 
test for the location in zero resulted in a P value of P=0.0006. 
To query about the presence of sign epistasis in the data we made pairwise comparisons 
between the fitness of each double resistance clone and its corresponding single 
resistance clones using a Wilcoxon test to assess if the fitness of the double resistant 
was higher than the fitness of any of the single resistance clones. The P values are 
indicated in Figure 3 for those combinations that provided significant results, at 5% 
confidence level, after Bonferroni correction (n=2 comparisons). For some of the double 
resistant clones created by P1 transduction that indicated the presence of sign epistasis- 
see Figure 3- we also obtained spontaneous double resistant mutants, that equally 
indicated evidence for sign epistasis.  
Epistasis is sometimes calculated assuming an additive model [41]: ε = cab – 
(ca+cb), such that it measures the deviation of the cost of carrying double resistance 
from the sum of the costs of each resistance. Since the values of the majority of the cost 
are small, applying the multiplicative or the additive model leads to the same 
conclusions, i.e. those combinations of alleles that lead to positive (negative) epistasis 
under the multiplicative model, also lead to positive (negative) epistasis under the 
additive model. A Kolmogorov-Smirnov comparing the distributions of ε under 
multiplicative model with under the additive model results on P=0.9. The median value 
in the distribution of epistasis calculated under the additive model is 0.025 with 
bootstrap 95% CI [0.015; 0.036] and a Wilcoxon test for location strongly supports the 
presence of positive epistasis: P=0.00002. This shows that the same pattern occurs 
ensuring either the multiplicative or the additive models. 
To perform the statistical analysis we used the free software R: http://www.r-
project.org. 
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Figure 1. Distribution of fitness costs of single and double mutants indicative of 
positive epistasis. A) Distribution of fitness costs of clones carrying single point 
mutations that confer resistance to streptomycin (black), rifampicin (dark grey) and 
nalidixic acid (light grey). B) Distribution of fitness costs of clones carrying double 
resistance to streptomycin/rifampicin (black), rifampicin/nalidixic acid (dark grey) and 
streptomycin/nalidixic acid (light grey). The mean fitness cost of double resistants is 
less than twice the mean cost of single resistance mutations.  
 
Figure 2. Evidence for positive epistasis. A) Relation between the observed fitness of 
the double resistance genotypes and the expected fitness under the assumption of no 
epistasis. B) Distribution of the epistasis level ε, whose median is 0.025 with bootstrap 
confidence interval [0.016, 0.032], showing positive epistasis. C) Allelic dependence of 
epistasis between the rpsL, rpoB and gyrA (positive epistasis in light grey, negative dark 
grey and not significant in white. Black indicates combinations of alleles for which 
there was a low efficiency of transduction - synthetic sub-lethals).  
 
Figure 3. Evidence for sign epistasis amongst alleles conferring resistance. Sign 
epistasis occurs when the fitness of the double mutant (white bar) is greater than the 
fitness of at least one single mutant (dark grey and light grey bars).  The genotypes of 
the double mutants where we found sign epistasis are indicated below the bars and the P 
values of the Wilcoxon test are indicated above the bars.   
 
Figure 4. Mutational spectrum and frequency of spontaneous double resistance 
mutations. Given the genetic background of the first mutation (column) the frequency 
of the second mutation (raw) appears as percentage in grey scale gradient. For a given 
background the percentage of mutations in the second locus adds up to 100%, in most 
cases, except when the second mutation occurred in a different gene. The percentage of 
the occurrence of each mutation in a wild-type background is also shown in the third 
column.  
 
 
 
 
 
 
 
 
 




